Menu
Search
|

Menu

Close
X

Recro Pharma Inc REPH.OQ (NASDAQ Stock Exchange Capital Market)

6.55 USD
+0.15 (+2.34%)
As of Nov 16
chart
Previous Close 6.40
Open 6.39
Volume 38,963
3m Avg Volume 35,747
Today’s High 6.56
Today’s Low 6.30
52 Week High 13.05
52 Week Low 4.78
Shares Outstanding (mil) 21.48
Market Capitalization (mil) 146.91
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
1.40 Mean rating from 5 analysts

KEY STATS

Revenue (mm, USD)
FY18
60
FY17
72
FY16
69
FY15
52
EPS (USD)
FY18
-1.911
FY17
-2.211
FY16
-2.814
FY15
0.103
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
29.34
Price to Sales (TTM)
vs sector
1.87
20.58
Price to Book (MRQ)
vs sector
10.47
4.23
Price to Cash Flow (TTM)
vs sector
--
21.19
Total Debt to Equity (MRQ)
vs sector
403.59
13.84
LT Debt to Equity (MRQ)
vs sector
403.59
9.93
Return on Investment (TTM)
vs sector
-43.48
13.58
Return on Equity (TTM)
vs sector
-172.82
15.11

EXECUTIVE LEADERSHIP

Wayne Weisman
Independent Chairman of the Board, Since 2008
Salary: --
Bonus: --
Geraldine Henwood
President, Chief Executive Officer, Director, Since 2008
Salary: $285,375.00
Bonus: $205,000.00
Ryan Lake
Chief Financial Officer, Since 2018
Salary: --
Bonus: --
Michael Celano
Chief Operating Officer, Since 2018
Salary: --
Bonus: --
Jyrki Mattila
Executive Vice President - Business Development, Since 2017
Salary: --
Bonus: --

COMPANY PROFILE

Sector: Healthcare
Industry: Biotechnology & Medical Research
Address:

490 Lapp Rd
MALVERN   PA   19355-1212

Phone: +1484.3952400

Recro Pharma, Inc. is a clinical-stage specialty pharmaceutical company. The Company is engaged in developing products for hospitals and ambulatory care settings that is developing non-opioid products for treatment of serious acute pain. The Company's lead product candidate is an injectable form of meloxicam. Its product candidates for pain indications include injectable meloxicam, a product candidate in development for the treatment of acute post-operative pain; Dex-IN, a product candidate under development for the treatment of post-operative pain; Dex-SL, a product candidate for the treatment of chronic pain, and Fadolmidine (Fado), a product candidate used by injection into the spine for pain associated with surgery or certain types of chronic pain and which the Company pursues as a topical product for local application to treat serious pain associated with nerve damage to local tissues (neuropathies), especially of the lower extremities, which can occur in diabetic patients.

SPONSORED STORIES